In this engaging discussion, researchers Caroline Naomi Valdez, Gabriela Athziri Sánchez-Zuno, Lais Osmani, Wael Ibrahim, Anjela Galan, and Antonietta Bacchiocchi delve into the roles of MIF and DDT in melanoma. They explore how these biomarkers could revolutionize treatment strategies and enhance prognosis. The team reveals intriguing correlations from a study involving 97 patients, suggesting that MIF may be a key target in overcoming immune checkpoint resistance. Their findings open the door for future advancements in melanoma therapy.
